158 related articles for article (PubMed ID: 23497539)
1. HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.
Habel LA; Sakoda LC; Achacoso N; Ma XJ; Erlander MG; Sgroi DC; Fehrenbacher L; Greenberg D; Quesenberry CP
Breast Cancer Res; 2013 Mar; 15(2):R24. PubMed ID: 23497539
[TBL] [Abstract][Full Text] [Related]
2. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.
Jansen MP; Sieuwerts AM; Look MP; Ritstier K; Meijer-van Gelder ME; van Staveren IL; Klijn JG; Foekens JA; Berns EM
J Clin Oncol; 2007 Feb; 25(6):662-8. PubMed ID: 17308270
[TBL] [Abstract][Full Text] [Related]
3. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer.
Ma XJ; Salunga R; Dahiya S; Wang W; Carney E; Durbecq V; Harris A; Goss P; Sotiriou C; Erlander M; Sgroi D
Clin Cancer Res; 2008 May; 14(9):2601-8. PubMed ID: 18451222
[TBL] [Abstract][Full Text] [Related]
4. Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.
Jankowitz RC; Cooper K; Erlander MG; Ma XJ; Kesty NC; Li H; Chivukula M; Brufsky A
Breast Cancer Res; 2011 Oct; 13(5):R98. PubMed ID: 21999244
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
Goetz MP; Suman VJ; Couch FJ; Ames MM; Rae JM; Erlander MG; Ma XJ; Sgroi DC; Reynolds CA; Lingle WL; Weinshilboum RM; Flockhart DA; Desta Z; Perez EA; Ingle JN
Clin Cancer Res; 2008 Sep; 14(18):5864-8. PubMed ID: 18794098
[TBL] [Abstract][Full Text] [Related]
6. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.
Ma XJ; Hilsenbeck SG; Wang W; Ding L; Sgroi DC; Bender RA; Osborne CK; Allred DC; Erlander MG
J Clin Oncol; 2006 Oct; 24(28):4611-9. PubMed ID: 17008703
[TBL] [Abstract][Full Text] [Related]
7. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.
Jerevall PL; Ma XJ; Li H; Salunga R; Kesty NC; Erlander MG; Sgroi DC; Holmlund B; Skoog L; Fornander T; Nordenskjöld B; Stål O
Br J Cancer; 2011 May; 104(11):1762-9. PubMed ID: 21559019
[TBL] [Abstract][Full Text] [Related]
8. Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome.
Jerevall PL; Brommesson S; Strand C; Gruvberger-Saal S; Malmström P; Nordenskjöld B; Wingren S; Söderkvist P; Fernö M; Stål O
Breast Cancer Res Treat; 2008 Jan; 107(2):225-34. PubMed ID: 17453342
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
Sgroi DC; Chapman JA; Badovinac-Crnjevic T; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Shepherd LE; Goss PE; Pollak M
Breast Cancer Res; 2016 Jan; 18(1):1. PubMed ID: 26728744
[TBL] [Abstract][Full Text] [Related]
10. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.
Sgroi DC; Carney E; Zarrella E; Steffel L; Binns SN; Finkelstein DM; Szymonifka J; Bhan AK; Shepherd LE; Zhang Y; Schnabel CA; Erlander MG; Ingle JN; Porter P; Muss HB; Pritchard KI; Tu D; Rimm DL; Goss PE
J Natl Cancer Inst; 2013 Jul; 105(14):1036-42. PubMed ID: 23812955
[TBL] [Abstract][Full Text] [Related]
11. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Ahmed I; Piper T; Salunga R; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
Ann Oncol; 2019 Nov; 30(11):1776-1783. PubMed ID: 31504126
[TBL] [Abstract][Full Text] [Related]
12. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Habel LA; Shak S; Jacobs MK; Capra A; Alexander C; Pho M; Baker J; Walker M; Watson D; Hackett J; Blick NT; Greenberg D; Fehrenbacher L; Langholz B; Quesenberry CP
Breast Cancer Res; 2006; 8(3):R25. PubMed ID: 16737553
[TBL] [Abstract][Full Text] [Related]
13. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer.
Wang Z; Dahiya S; Provencher H; Muir B; Carney E; Coser K; Shioda T; Ma XJ; Sgroi DC
Clin Cancer Res; 2007 Nov; 13(21):6327-34. PubMed ID: 17975144
[TBL] [Abstract][Full Text] [Related]
14. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.
Sgroi DC; Treuner K; Zhang Y; Piper T; Salunga R; Ahmed I; Doos L; Thornber S; Taylor KJ; Brachtel E; Pirrie S; Schnabel CA; Rea D; Bartlett JMS
Breast Cancer Res; 2022 Dec; 24(1):90. PubMed ID: 36527133
[TBL] [Abstract][Full Text] [Related]
15. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
16. Association of miR-1266 with recurrence/metastasis potential in estrogen receptor positive breast cancer patients.
Sevinc ED; Egeli U; Cecener G; Tezcan G; Tunca B; Gokgoz S; Tasdelen I; Tolunay S; Evrensel T
Asian Pac J Cancer Prev; 2015; 16(1):291-7. PubMed ID: 25640367
[TBL] [Abstract][Full Text] [Related]
17. Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer.
Jerevall PL; Jansson A; Fornander T; Skoog L; Nordenskjöld B; Stål O
Breast Cancer Res; 2010; 12(4):R53. PubMed ID: 20649975
[TBL] [Abstract][Full Text] [Related]
18. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR
Noordhoek I; Treuner K; Putter H; Zhang Y; Wong J; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; van de Velde CJH; Schnabel CA; Liefers GJ
Clin Cancer Res; 2021 Jan; 27(1):311-319. PubMed ID: 33109739
[TBL] [Abstract][Full Text] [Related]
19. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen.
Goetz MP; Suman VJ; Ingle JN; Nibbe AM; Visscher DW; Reynolds CA; Lingle WL; Erlander M; Ma XJ; Sgroi DC; Perez EA; Couch FJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2080-7. PubMed ID: 16609019
[TBL] [Abstract][Full Text] [Related]
20. Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis.
Zhao L; Zhu S; Gao Y; Wang Y
Tumour Biol; 2014 Apr; 35(4):3113-7. PubMed ID: 24264313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
